Argenx Announces FDA Approval Of Vyvgart Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy
ARGENX ANNOUNCES FDA APPROVAL OF VYVGART HYTRULO PREFILLED SYRINGE FOR SELF-INJECTION IN GENERALIZED MYASTHENIA GRAVIS AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.